Zymeworks Inc
ZYME12.450USD
-0.120-0.95%
交易中 （美东）报价延迟15分钟
873.43M总市值
亏损市盈率 TTM
关于 Zymeworks Inc 公司
Zymeworks Inc. 是一家全球性生物技术公司。该公司致力于发现、开发和商业化用于治疗癌症和其他严重疾病的多功能生物治疗药物。其互补的治疗平台和完全集成的药物开发引擎提供了灵活性和兼容性，可以精确设计和开发差异化的基于抗体的治疗候选药物。其平台包括 Azymetric、药物偶联物平台、EFECT 和 ProTECT。其主要候选产品 zanidatamab 是一种双特异性抗体，靶向人类表皮生长因子受体 2 (HER2) 的两个不同域。其第二个候选产品 zanidatamab zovodotin 将 zanidatamab 的双位抗体设计与其 ZymeLink auristatin 抗体-药物偶联物 (ADC) 技术相结合，由其细胞毒素（癌细胞杀伤化合物）和可裂解接头组成。其产品线包括四种临床前候选药物：ZW191、ZW171、ZW220 和 ZW251。
公司简介
公司代码ZYME
公司名称Zymeworks Inc
上市日期Jun 24, 2019
CEOMr. Kenneth H. (Ken) Galbraith
员工数量280
证券类型Ordinary Share
年结日Jun 24
公司地址108 Patriot Drive, Suite A
城市MIDDLETOWN
上市交易所NASDAQ Global Select Consolidated
国家United States of America
邮编19709
电话13022748744
网址https://www.zymeworks.com/
公司代码ZYME
上市日期Jun 24, 2019
CEOMr. Kenneth H. (Ken) Galbraith
公司高管
名称
名称/职务
职务
持股
持股变动
Mr. Troy M. Cox
Mr. Troy M. Cox
Independent Director
Independent Director
7.50K
--
Dr. Sabeen Mekan, M.D.
Dr. Sabeen Mekan, M.D.
Senior Vice President - Clinical Development
Senior Vice President - Clinical Development
--
--
Dr. Kelvin M. Neu ,M.D.
Dr. Kelvin M. Neu ,M.D.
Independent Director
Independent Director
--
--
Mr. Scott Platshon
Mr. Scott Platshon
Independent Director
Independent Director
--
--
Dr. Alessandra Cesano, M.D., Ph.D.
Dr. Alessandra Cesano, M.D., Ph.D.
Independent Director
Independent Director
--
--
Ms. Leone D. Patterson, CPA
Ms. Leone D. Patterson, CPA
Chief Financial Officer, Chief Business Officer, Executive Vice President
Chief Financial Officer, Chief Business Officer, Executive Vice President
--
--
Mr. Kenneth H. (Ken) Galbraith
Mr. Kenneth H. (Ken) Galbraith
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
--
--
Dr. Neil Gallagher, M.D., Ph.D.
Dr. Neil Gallagher, M.D., Ph.D.
Independent Director
Independent Director
--
--
Mr. Carlos E. Campoy
Mr. Carlos E. Campoy
Independent Director
Independent Director
--
--
Dr. Susan M. (Sue) Mahony, Ph.D.
Dr. Susan M. (Sue) Mahony, Ph.D.
Lead Independent Director
Lead Independent Director
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Mr. Troy M. Cox
Mr. Troy M. Cox
Independent Director
Independent Director
7.50K
--
Dr. Sabeen Mekan, M.D.
Dr. Sabeen Mekan, M.D.
Senior Vice President - Clinical Development
Senior Vice President - Clinical Development
--
--
Dr. Kelvin M. Neu ,M.D.
Dr. Kelvin M. Neu ,M.D.
Independent Director
Independent Director
--
--
Mr. Scott Platshon
Mr. Scott Platshon
Independent Director
Independent Director
--
--
Dr. Alessandra Cesano, M.D., Ph.D.
Dr. Alessandra Cesano, M.D., Ph.D.
Independent Director
Independent Director
--
--
Ms. Leone D. Patterson, CPA
Ms. Leone D. Patterson, CPA
Chief Financial Officer, Chief Business Officer, Executive Vice President
Chief Financial Officer, Chief Business Officer, Executive Vice President
--
--
收入明细
暂无数据
暂无数据
业务
地区
暂无数据
股东统计
更新时间: 7月27日 周日
更新时间: 7月27日 周日
持股股东
股东类型
持股股东
持股股东
占比
EcoR1 Capital, LLC
30.69%
Redmile Group, LLC
6.40%
Rubric Capital Management LP
5.80%
BVF Partners L.P.
5.76%
BlackRock Institutional Trust Company, N.A.
4.54%
Other
46.81%
持股股东
持股股东
占比
EcoR1 Capital, LLC
30.69%
Redmile Group, LLC
6.40%
Rubric Capital Management LP
5.80%
BVF Partners L.P.
5.76%
BlackRock Institutional Trust Company, N.A.
4.54%
Other
46.81%
股东类型
持股股东
占比
Investment Advisor/Hedge Fund
50.16%
Investment Advisor
25.24%
Hedge Fund
17.77%
Research Firm
5.28%
Private Equity
2.49%
Venture Capital
0.92%
Bank and Trust
0.36%
Sovereign Wealth Fund
0.27%
Pension Fund
0.26%
机构持股
更新时间: 7月1日 周二
更新时间: 7月1日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q2
381
77.02M
102.91%
+3.16M
2025Q1
400
71.70M
97.61%
-1.37M
2024Q4
389
68.69M
99.73%
-8.79M
2024Q3
388
74.13M
105.03%
-25.13M
2024Q2
387
74.77M
106.29%
-27.88M
2024Q1
389
74.54M
106.20%
-28.73M
2023Q4
388
72.09M
103.65%
-29.69M
2023Q3
376
69.54M
103.06%
-33.91M
2023Q2
364
70.30M
109.70%
-27.74M
2023Q1
340
64.28M
100.47%
-34.07M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
EcoR1 Capital, LLC
22.97M
30.69%
+5.09M
+28.44%
Jun 26, 2025
Redmile Group, LLC
4.79M
6.4%
-51.52K
-1.06%
Mar 31, 2025
Rubric Capital Management LP
4.34M
5.8%
+421.11K
+10.75%
Mar 31, 2025
BVF Partners L.P.
4.31M
5.76%
--
--
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
3.40M
4.54%
-93.86K
-2.69%
Mar 31, 2025
Morgan Stanley & Co. LLC
3.30M
4.42%
-169.56K
-4.88%
Mar 31, 2025
UBS Asset Management (Switzerland)
2.24M
2.99%
+918.38K
+69.53%
Mar 31, 2025
BNP Paribas Asset Management USA, Inc.
2.20M
2.94%
+222.17K
+11.25%
Mar 31, 2025
Perceptive Advisors LLC
1.86M
2.49%
-265.35K
-12.46%
Mar 31, 2025
The Vanguard Group, Inc.
1.76M
2.35%
-718.49K
-28.98%
Mar 31, 2025
查看更多
持股ETF
更新时间: 8月2日 周六
更新时间: 8月2日 周六
机构名称
占比
Virtus LifeSci Biotech Clinical Trials ETF
0.86%
Tema Oncology ETF
0.86%
iShares Micro-Cap ETF
0.14%
Federated Hermes MDT Small Cap Core ETF
0.1%
Invesco Nasdaq Biotechnology ETF
0.1%
ProShares Ultra Nasdaq Biotechnology
0.1%
iShares Biotechnology ETF
0.09%
iShares MSCI USA Small-Cap Min Vol Factor ETF
0.09%
SPDR S&P International Small Cap ETF
0.06%
iShares ESG Aware MSCI USA Small-Cap ETF
0.05%
查看更多
Virtus LifeSci Biotech Clinical Trials ETF
占比0.86%
Tema Oncology ETF
占比0.86%
iShares Micro-Cap ETF
占比0.14%
Federated Hermes MDT Small Cap Core ETF
占比0.1%
Invesco Nasdaq Biotechnology ETF
占比0.1%
ProShares Ultra Nasdaq Biotechnology
占比0.1%
iShares Biotechnology ETF
占比0.09%
iShares MSCI USA Small-Cap Min Vol Factor ETF
占比0.09%
SPDR S&P International Small Cap ETF
占比0.06%
iShares ESG Aware MSCI USA Small-Cap ETF
占比0.05%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
